News & Updates
Filter by Specialty:
Nonhormonal drug for hot flash scores big in two phase III trials
The novel neurokinin-1 and -3 receptor antagonist elinzanetant appears to reduce the frequency and severity of vasomotor symptoms (VMS), as well as improve sleep and menopause-related quality of life, as shown in two pivotal phase III trials.
Nonhormonal drug for hot flash scores big in two phase III trials
02 Nov 2024
Dietary intake of n-3 PUFA prevents all-cause, CV deaths in diabetic people
Individuals with prediabetes or diabetes may benefit from increased dietary intake of n-3 polyunsaturated fatty acids (PUFAs), particularly alpha-linolenic acid (ALA) and docosapentaenoic acid (DPA), which help lower the risk of all-cause and cardiovascular mortality, suggests a US study.
Dietary intake of n-3 PUFA prevents all-cause, CV deaths in diabetic people
02 Nov 2024
RSV may worsen clinical outcomes in HF patients
A retrospective analysis presented at HSFA ASM 2024 shows that respiratory syncytial virus (RSV) infection in individuals with heart failure (HF) is associated with greater adverse clinical outcomes.
RSV may worsen clinical outcomes in HF patients
01 Nov 2024
Sacubitril/valsartan maintains efficacy, safety in HF patients with hypotension
Both symptomatic and asymptomatic hypotension are associated with worse outcomes during treatment with either enalapril or sacubitril/valsartan, but the benefits derived from the combination therapy are maintained or even improved in heart failure (HF) patients with hypotension, a study has shown.
